Anti-amyloid treatment for Alzheimer’s disease has recently entered clinical use. The ability of anti-amyloid drugs to slow the progression of dementia is unprecedented. However, it is unknown how patients and their caregivers value a delayed course of cognitive impairment and how they weigh its significance against the burdens posed by anti-amyloid treatment. In this study, we are interviewing and observing patients, caregivers, and clinicians as they make decisions about anti-amyloid treatment and interpret its effects. We will use our findings to advance the ethical usage of anti-amyloid drugs and inform how clinicians communicate about these drugs with patients and families.